+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768262
  • Report
  • April 2019
  • Region: Global
  • 173 pages
  • VPA Research
UP TO OFF
until Oct 31st 2021

FEATURED COMPANIES

  • Amgen Inc
  • CSL Ltd
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Grifols SA
The global clinical trial report- “2019 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). It presents in-depth analysis of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

The research work is prepared through extensive and continuous research on Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) patients are identified
  • The report includes panorama of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • CSL Ltd
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Grifols SA
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Region
2.2.2 Average Enrollment of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Treatment, 2019

3. Region wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
3.1 Asia Pacific Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Country
3.2 Europe Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Country
3.3 North America Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Country
3.4 Middle East and Africa Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Country
3.5 South and Central America Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Country

4. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trial Trends
4.1 Start Year wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
4.2 Phase wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
4.3 Trial Status wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
4.4 Trial Type wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials

5. Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment Trends
5.1 Average Enrollment in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials by Year
5.2 Average Enrollment in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials by Phase
5.3 Average Enrollment in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials by Status
5.4 Average Enrollment in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials by Type of Trial

6. Companies Participating in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials
6.1 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials by Sponsor Type
6.2 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials- Phase 1
7.2 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials- Phase 2
7.3 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials- Phase 3
7.4 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Figure 7: North America - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Figure 9: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Phase
Figure 10: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Trial Status
Figure 11: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Type
Figure 12: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Sponsor Type
Figure 13: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials by Leading Sponsors
Figure 14: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Phase
Figure 15: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Trial Status
Figure 16: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Type
Figure 17: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)- Average Enrolment by Type of Sponsors
Figure 18: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Table 5: Europe - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Table 7: North America - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Phase
Table 15: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Trial Status
Table 16: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Average Enrollment by Type
Table 17: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)- Average Enrolment by Type of Sponsors
Table 18: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Amgen Inc
  • C. H. Boehringer Sohn AG & Co KG
  • CSL Ltd
  • Eisai Co Ltd
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Grifols SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll